Submitting the first US proposal for an OTC daily oral contraceptive weeks after acquiring the product’s developer and soon after receiving its first approval for an Rx-to-OTC switch wasn’t enough momentum into the second half of the year for Perrigo Company PLC.
Along with its second-quarter results including reported net sales up 14.3% to $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?